Certest Presents Newly-Released SARS-CoV-2 Diagnostic Products at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 29 Sep 2021

Image: VIASURE Real Time PCR Detection Kit (Photo courtesy of CerTest Biotec)

CerTest Biotec (Zaragoza, Spain) introduced all the new releases developed by the company in recent months, especially its products focused on the diagnosis of SARS-CoV-2, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

Among its new releases highlighted by CerTest at AACC 2021 were the VIASURE Tropical Panel I Real Time PCR Detection Kit designed for the specific and differentiation of Zika (ZIKV), Dengue (DENV), Chikungunya (CHIKV), West Nile (WNV), Yellow fever (YFV) and/or Mayaro (MYV) viruses; and the FOB Turbilatex non-invasive immunological test for bowel cancer screening.

CerTest’s new products for the diagnosis of SARS-CoV-2 that were exhibited at the event included the CerTest CLIA SARS-CoV-2 Plate which is an antigen detection product; the CerTest SARS-CoV-2 one step card test which is a colored chromatographic immunoassay for the qualitative detection of SARS-CoV-2 from nasopharyngeal swab samples from patients with sign and symptoms of COVID-19 infection; and the VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit for the qualitative detection of RNA from genetic mutations in the S gene (P681R, L452R and E484Q) from positive SARS-CoV-2 nasopharyngeal samples.

CerTest also used the event as a launching pad for its new Business Units: CerTest CLIA, BioSynProbes and CerTest Vaccines, which were represented at the company’s booth. According to the company, the new business units will complete the portfolio of comprehensive solutions not only for the diagnosis of infectious diseases, but also in the manufacturing processes of clinical tests and disease cure.

Related Links:
CerTest Biotec